Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes

被引：0
|
作者：
Meidong Zhu
Jamie K. Chew
Geoffrey K. Broadhead
Kehui Luo
Nichole Joachim
Thomas Hong
Adil Syed
Andrew A. Chang
机构：
[1] Sydney Institute of Vision Science,Save Sight Institute
[2] The University of Sydney,Statistics Department
[3] Macquarie University,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2015年 / 253卷
关键词：
Ranibizumab; Neovascular age-related macular degeneration (nAMD); As-needed treatment model; Five-year treatment; Exudative age-related macular degeneration; Wet macular degeneration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1217 / 1225
页数：8
相关论文
共 50 条
  • [31] Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
    Rachel Hui Fen Lim
    Bhaskar Gupta
    Peter Simcock
    International Journal of Ophthalmology, 2017, (03) : 423 - 426
  • [32] Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
    Lim, Rachel Hui Fen
    Gupta, Bhaskar
    Simcock, Peter
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (03) : 423 - 426
  • [33] Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration
    Pushpoth, Sreekumari
    Sykakis, Evripidis
    Merchant, Kinnar
    Browning, Andrew C.
    Gupta, Rajen
    Talks, S. James
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (12) : 1469 - 1473
  • [34] Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
    Sabour-Pickett, Sarah
    Loughman, James
    Nolan, John M.
    Stack, Jim
    Pesudovs, Konrad
    Meagher, Katherine A.
    Beatty, Stephen
    JOURNAL OF OPHTHALMOLOGY, 2013, 2013
  • [35] Efficacy of intravitreal aflibercept treatment of pigment epithelial detachment in neovascular age-related macular degeneration refractory to intravitreal ranibizumab: 2-year outcomes
    Ramskold, Louise
    Lee, Han Bin
    Chandran, Manju N.
    Gencheva, Petya
    Menon, Geeta
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [36] Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
    Khanani, Arshad M.
    Gahn, Greggory M.
    Koci, Micaela M.
    Dang, Jonathan M.
    Brown, Sandra M.
    Hill, Lauren F.
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 347 - 351
  • [37] Ranibizumab (Lucentis) in neovascular age-related macular degeneration (AMD): five year follow up
    Cvetkova, Nadezhda
    Maerker, David
    Helbig, Horst
    Hoelldobler, Kristina
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [38] Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration The Comparison of Age-Related Macular Degeneration Treatments Trials
    Maguire, Maureen G.
    Martin, Daniel F.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Daniel, Ebenezer
    Grunwald, Juan E.
    Toth, Cynthia A.
    Ferris, Frederick L., III
    Fine, Stuart L.
    OPHTHALMOLOGY, 2016, 123 (08) : 1751 - 1761
  • [39] One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups
    Seungbum Kang
    Young-Jung Roh
    Japanese Journal of Ophthalmology, 2009, 53 : 389 - 395
  • [40] One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups
    Kang, Seungbum
    Roh, Young-Jung
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2009, 53 (04) : 389 - 395
12345